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Abstract
Background: In the 1990s, epidemiological studies estimated the prevalence of stroke caused by atrial fibrillation (AF)
at about 15 %. Given the aging population, there is a rise in the number of AF patients. AF prevention guidelines based
on clinical practice and the literature have been published and updated since 2001. Implementation seems to have an
impact on the prescription of vitamin K antagonist (VKA). During the last 20 years, few population-based studies have
focused on the prevalence of atrial arrhythmia (AA) in patients with stroke. The objective of the present prospective
study, using data from 2008, was to evaluate the prevalence of AA (atrial fibrillation/flutter) in patients with stroke and
the impact of implementing AF guidelines.
Methods: The prevalence of AA was studied in patients diagnosed with stroke from January 1 to December 31, 2008
in the population-based Stroke Registry of Brest, France (total population, 363,760 according to the 2008 census, with
295,553 aged 15 years or older). Guidelines implementation was assessed in terms of antithrombotic therapy
(VKA, antiplatelet agent, none), and the CHADS2 (Congestive heart failure, Hypertension, Age > 75 years, Diabetes
mellitus, and prior Stroke or transient ischemic attack).
Results: 851 cases of stroke were identified. The prevalence of AA was 31.7 % (n = 264), and increased with age
from < 20 % in patients aged 45 to 54 years to nearly 50 % in patients ≥ 85 years. In patients with AA, 231 strokes
were ischemic, 28 hemorrhagic and 5 undetermined. At time of stroke, AA was known in 207 patients (78.4 %).
54 of the 152 patients with CHADS2 score ≥ 2 (35.5 %) were treated with VKA; this proportion decreased with age:
50 % between 50 and 74 years, 43.8 % between 75 and 84 years, and 25 % at 85 years and older.
Conclusion: The prevalence of AA in the population-based Brest Stroke Registry in 2008 was higher than that
reported by studies conducted 20 years ago. Despite publication of AF prevention guidelines, VKA prescription
and use in elderly patients were significantly low.
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Background
Atrial fibrillation (AF) is a public health problem because
of its epidemiology and severity: it is the most common
form of cardiac arrhythmia, affecting approximately 1 %
of adults [1]. Prevalence increases with age, from < 0.5 %
at 40 to 50 years, to > 10 % at 80 years or older [1].
In population-based studies, incidence increased from
< 0.1 % per year before 40 years to > 1.5 % after 80 years
[2]. Given the aging population, the number of patients
with AF is expected to rise. AF is associated with in-
creased risks of: mortality [3], heart failure [4], dementia
[5] and systemic embolism, with a 5-fold increase in risk
of stroke [6]. Stroke due to AF shows higher mortality
and worse outcome than stroke due to atherosclerosis
[7]. AF is commonly associated with other risk factors
for stroke: age, female gender, hypertension, prior stroke
or transient ischemic attack (TIA), systolic congestive
heart failure, diabetes mellitus, and vascular disease [8].
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Warfarin has been shown to be highly effective in pre-
venting stroke in AF [9, 10]. American (ACC/AHA) and
European (ESC) guidelines have been established for
clinical practice. The risk of thromboembolism (TE)
was evaluated on the basis of CHADS2 score (Congest-
ive heart failure, Hypertension, Age > 75 years, Diabetes
mellitus, and prior Stroke or transient ischemic attack)
scores in 2001 [11] and 2006 [12]; the CHADS2 score
was replaced by CHA2DS2 Vasc in 2010 [13]. Thrombo-
prophylaxis in AF requires assessment of both stroke
and bleeding risks. Despite its proven benefit, warfarin
is underused in AF patients, and in particular in the eld-
erly [14–16]. TE risk in atrial flutter has been less well
assessed than in AF, but is estimated to be intermediate
compared to sinus rhythm or AF [17].
In the 1990s, before the publication of AF prevention
guidelines, epidemiological studies estimated prevalence
of AF-related stroke at about 15 % [18].
During the last 20 years, few population-based studies
have focused on the prevalence of arrhythmia in stroke.
Given the aging population, there is a rise in the number
of AF patients. AF prevention guidelines based on clin-
ical practice and the literature have been published and
updated since 2001. Implementation seems to have an
impact on the prescription of vitamin K antagonist
(VKA). The main objective of the present prospective
study based on 2008 data was to evaluate the prevalence
of atrial arrhythmia (AA) (atrial fibrillation/flutter) and
the impact of implementation of prevention guidelines
on CHADS2 scores in a stroke population. The second-
ary objective was to calculate the CHA2DS2Vasc score
to estimate the number of patients at high risk of TE
and requiring anticoagulation according to current
guidelines.
Methods
The prevalence of AA was studied in patients diagnosed
with stroke from January 1, 2008 to December 31, 2008,
in the population-based Stroke Registry of Brest (France).
Study population
A description of the Brest Stroke Registry has been pub-
lished previously [19].
The Brest Stroke Registry is a population-based regis-
try covering the Brest area, in northwest France: popula-
tion, 363,760 according to the 2008 census, with 295,553
aged 15 years or older.
Case ascertainment
All residents of the Brest area with stroke were taken
into account. To ensure exhaustive ascertainment, data
were collected from several local sources: two teaching
hospitals (Brest University Hospital and Clermont-
Tonnerre Military Hospital, both in Brest) and one
general hospital (Ferdinand Grall Hospital, in nearby
Landerneau), general practitioners, three neurologists
in private practice, private radiology centers, nursing
homes, and finally from death certificates, providing
data for fatal stroke in non-hospitalized subjects.
Stroke definition and classification
Two previously described definitions of stroke were
considered [19]: 1) new focal neurological deficit with
symptoms and signs in line with the World Health
Organization definition of stroke [20], lasting for more
than 24 h (patients with focal neurological deficit who
died within the first 24 h were also included); and 2) all
neurological focal deficits lasting at least 1 h or resolv-
ing within 1 h but with abnormal brain imaging associ-
ated with a clinically relevant picture [19]. An abnormal
image was defined as an image visible on CT or MRI
scan showing ischemic or hemorrhagic stroke, the loca-
tion of which may explain the clinical presentation. Sub-
arachnoid hemorrhage was excluded from the study.
Subtype diagnosis by neurologists of the Department of
Neurology was based on clinical examination, cerebral
imaging (CT or MRI), and complementary investiga-
tions including carotid and vertebral ultrasonography,
and echocardiography. Stroke was classified as ischemic,
hemorrhagic or “unknown” subtype according to the
Oxfordshire Community Stroke Project (OCSP) classifi-
cation [21]. Cerebral infarctions were classified accord-
ing to the Trial of Org 10172 in Acute Stroke Treatment
classification (TOAST) [22] and the Stop Stroke Study
TOAST (SSS-TOAST) [23]: thrombosis or embolism
due to atherosclerosis of a large artery, embolism of car-
diac origin, occlusion of a small blood vessel, other de-
termined cause, or undetermined cause (two or more
causes identified, negative assessment, or incomplete as-
sessment). An automated version of the SSS-TOAST
was used for the registry [24].
AA was diagnosed in patients with atrial fibrillation/
flutter known at the time of stroke, and/or in patients
classified as having permanent or paroxysmal atrial fib-
rillation or atrial flutter on the basis of the SSS-TOAST
for cerebral infarction. In patients with intracranial
hemorrhage and “undetermined” stroke with AA un-
known at the time of the stroke, all electrocardiograms
(ECG) were analyzed and the general practitioner was
contacted by phone to check for the history of AA.
In patients with AA known at the time of the stroke,
the CHADS2 score was calculated to assess the impact of
implementation of TE prevention guidelines. (CHADS2,
and not the later CHA2DS2 Vasc, was the score in use at
the time of the study [12]). The following data were
recorded: age according to demographic data; history of
hypertension, diabetes mellitus, and prior stroke or TIA
according to medical records, and history of congestive
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heart failure on SSS-TOAST for cerebral infarction. The
CHADS2 score was obtained by assigning and adding
points: 1 point for each moderate risk factor (heart failure,
hypertension, age, and diabetes mellitus) and 2 points for
history of stroke or TIA. Patients were assigned to one of
three classes of TE-related stroke risk: low risk (CHADS2
score = 0), intermediate risk (CHADS2 score = 1), or high
risk (CHADS2 score ≥ 2). Patients with missing data were
classified as “unknown”. For each patient for whom
CHADS2 was calculated, the antithrombotic therapy pre-
scribed at the time of stroke was classified as follows: no
therapy, platelet aggregation inhibitors (aspirin and/or clo-
pidogrel), or anticoagulation with VKA. The International
Normalized Ratio (INR) was measured at admission. The
prescribed antithrombotic therapy was compared to the
recommended treatment according to CHADS2 score: i.e.,
VKA at a dose adjusted to achieve an INR within the
therapeutic range (between 2 and 3) in high-risk patients
(CHADS2 score ≥ 2); aspirin at a dose of 75 to 325 mg
daily in low risk patients (CHADS2 score = 0); or VKA or
aspirin according to the clinical context and patient’s
preference in patients at moderate risk of TE (CHADS2
score = 1).
The CHA2DS2 Vasc score was then calculated for
patients with AA known at the time of stroke, according
to the scoring used for CHADS2. Additional data were
collected: female gender from demographic data, periph-
eral artery disease and prior myocardial infarction from
medical records, and aortic plaque (>4 mm) according
to SSS-TOAST for cerebral infarction. Patient distribu-
tions according to CHADS2 and CHA2DS2 Vasc scores
were compared.
Statistical analysis
Statistical analysis used SAS software. EpiData 3.1 soft-
ware was used for registry data entry. Median and mean
ages were calculated, with quartiles and standard devia-
tions respectively. Frequencies were calculated for gender,
Fig. 1 Prevalence of atrial arrhythmia-related stroke in 2008, by age and gender. Legend: CI: Confidence Interval
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prior stroke, prior TIA, myocardial infarction, hyperten-
sion, and diabetes mellitus. Missing data were also calcu-
lated and variables with more than 10 % missing data
were discarded. Prevalence of AA according to gender
and age was calculated.
Ethics
The Brest Stroke Registry was approved by the national
ethics committee (CNIL) and the French Public Health
Watch Institute (InVS).
Results
In 2008, 851 strokes were recorded: 733 ischemic (86 %),
96 hemorrhagic (11 %), and 22 undetermined (3 %). 383
of the patients were male (45 %) and 468 female. Mean
age was 75.5 ± 13.6 years and median age 79 years.
Sixteen patients were excluded because they did not
undergo ECG or cardiac monitoring at admission, medical
history was unknown or the general practitioner could not
provide data on possible AA (general practitioner un-
known, cessation of private practice, or archiving of med-
ical records).
264 of the remaining 835 patients (31.7 %) had AA
(AF or flutter). Mean and median ages for patients with
AA were 81.1 ± 8.9 years and 83 years (range, 77–87 years),
respectively. There were 152 women (57.6 %) and 112
men (42.4 %). As shown in Fig. 1, prevalence of AA in-
creased with age in both genders. 231 of the 264
strokes associated with AA were ischemic (87.5 %), 28
hemorrhagic (10.6 %), and 5 undetermined (1.9 %).
The distribution between atrial fibrillation and atrial
flutter is described in Fig. 2: 138 patients with ischemic
stroke had permanent AF (59.7 %), 61 paroxysmal AF
(26.4 %) and 3 atrial flutter (1.3 %); AA type was un-
determined in 29 (12.6 %). In 207 patients (78.4 %), AA
was already known at the time of stroke. The demo-
graphic and baseline characteristics of the 264 patients
are presented in Table 1.
231 of the 733 patients with ischemic stroke recorded
in 2008 had AA (31.5 %).
CHADS2 score was calculated for the 207 patients
with AA known prior to stroke: 10 (4.8 %) scored 0 and
33 (15.9 %) scored 1. Antithrombotic therapy according
to CHADS2 score is shown in Table 2. 54 of the 152 pa-
tients (73.4 %) with CHADS2 score ≥ 2 received VKA
Fig. 2 Flowchart of patients throughout the study. Legend: AA: Atrial Arrhythmia; AF: Atrial Fibrillation
Table 1 Demographics and Baseline Characteristics of the
Population
Number N (%) Missing data N (%)
Median age (quartiles) 83 (77–87) 0
Mean age and SD 81.1 +/−8.9 0
Male 112 (42.4 %) 0
Female 152 (57.6 %) 0
Atrial arrhythmia 207 (78.4 %) 3 (1.1 %)
Prior stroke 68 (25.8 %) 8 (3 %)
Prior TIA 30 (11.4 %) 17 (6.4 %)
Myocardial infarction 43 (16.4 %) 20 (7.6 %)
Hypertension 175 (66.3 %) 11 (4.2 %)
Diabetes mellitus 37 (14 %) 14 (5.3 %)
Legend: SD: Standard deviation, TIA: Transient Ischemic Attack
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(35.5 %), associated with aspirin in 3 cases. INR (<2, [2, 3],
>3) according to CHADS2 score in patients on VKA is
shown in Table 3; in 2 cases, INR was undetermined.
The proportion of patients at high risk of TE with
CHADS2 score ≥ 2 receiving VKA decreased with age:
50 % for 50–74 years, 43.8 % for 75–84 years, and 25 %
for ≥ 85 years.
CHA2DS2 Vasc was also calculated in the 207 patients
with AA known prior to stroke. Distribution according
to CHADS2 and CHA2DS2 Vasc scores is shown in
Fig. 3: 195 patients were classified as being at high risk
of TE on CHA2DS2Vasc, compared to 152 on CHADS2.
Nine of the 28 patients (32.1 %) with hemorrhagic
stroke and AA were on antiplatelet therapy, 14 (50 %)
on VKA, 1 on antiplatelets and VKA, and 4 (14.3 %) had
no antithrombotic therapy. For the 15 patients on VKA,
INR was within therapeutic range, > 3 and <2, in 10, 2
and 3 patients, respectively.
Discussion
The prevalence of AA-related stroke was 31.7 % in our
registry, higher than in previous population-based studies,
where proportions of AF-related stroke were between 18
and 24 % [25, 26]. These population based-studies were
conducted before the publication of the AF guidelines.
Given the differences in age and gender distributions
in AA-associated stroke, comparison of AA prevalence
is difficult. However, the present results are consistent
with those reported by the North Dublin Population
Stroke Study in 2010 [27]. In this recent study, including
patients between 2005 and 2006, the authors observed
that 31.2 % of strokes (ischemic or hemorrhagic) were
associated with AF. We compared our results with those
of Marini et al.[26] and the North Dublin Population
Stroke Study [27] on prevalence analysis by age group
and gender: our results showed a higher prevalence than
Marini et al. in men for all age groups and for women
< 60 years and women > 80 years. Prevalence analysis
by age group showed lower prevalence for patients <
84 years than in Dublin registry, but slightly higher
prevalence for patients aged ≥ 85 years.
Thus the discrepancy between the present AA-related
stroke prevalence and those reported before the AF
guidelines may be explained by the difference in AA
diagnosis technology and patient management. In 2008,
electrocardiograms were monitored in day-care, whereas
they were not routinely performed 20 years ago (e.g., in
the 1992 Oxfordshire study [18]). Since then, the
widespread use of Holter ECG combined with the de-
velopment of stroke units and telemetry monitoring
during the first 48 h of acute ischemic stroke have led
to higher rates of diagnosis of paroxysmal AF not pre-
viously diagnosed by medical history, ECG or 24 h
Holter ECG. The present study thus included patients
with paroxysmal AF or atrial flutter, whereas previous
studies included only patients with permanent AF. In
our registry, 61 ischemic strokes were associated with
paroxysmal AF (26.4 %), and 4 with atrial flutter only
(1.5 %). The increasing prevalence of stroke associated
with AA could partly be explained by population aging in
developed countries [28]. In the present study, prevalence
was also higher than in hospital-based studies [29], prob-
ably because our population included a higher proportion
of very elderly patients, at high risk of AF.
In the present study, AA was known prior to stroke in
almost 80 % of cases, probably reflecting good AA
Table 2 Antithrombotic therapy according to CHADS2 score
aspirin clopidogrel aspirin + clopidogrel VKA no antithrombotic therapy
CHADS2 unknown 1 0 0 8 3
CHADS2 = 0 2 2 0 2 4
CHADS2 = 1 7 0 0 12 14
CHADS2≥ 2 60 8 1 54, including 3 patients on both aspirin and VKA. 29
Legend: VKA: Vitamin K Antagonist
Table 3 INR according to the CHADS2 score, in patients with
VKA
INR < 2 2–3 INR > 3
CHADS2 = 0 2 (100 %) 0 0
CHADS2 = 1 9 (75 %) 3 (25 %) 0
CHADS2≥ 2 29 (55.8 %) 18 (34.6 %) 5 (9.6 %)
Legend: INR: International Normalized Ratio, VKA: Vitamin K Antagonist
























Fig. 3 Distribution of patients with atrial arrhythmia known prior to
stroke according to CHADS2 and CHA2DS2 scores
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diagnosis. In the North Dublin Population Stroke Study
[27], 54.4 % of patients had diagnosis of AF prior to
stroke: in other studies, AF was known at the time of
stroke in 65 % to 83 % of patients [14, 30, 31].
36.7 % of our patients with AA diagnosed prior to
stroke were on VKA, comparably to other hospital- or
population-based studies [15, 27, 31, 32]. This under-
prescription of oral anticoagulants has also been ob-
served in the general population (out- and in-patients),
despite the absence of known contraindications [33].
Furthermore, in our registry, only 35.5 % of the high
TE risk patients with CHADS2 score ≥ 2 were treated
with VKA as recommended, and 45.4 % were treated
with antiplatelet agents. Underuse of VKA therapy in
the present study increased with age: only 25 % of
patients aged ≥ 85 years were on VKA. This underuse
of anticoagulant therapy in the elderly was observed in
previous studies: < 60 % of patients in the report by
Ogilvie et al. [14]. Several hypotheses may explain this:
physician’s underestimation of AF-related TE risk;
physician’s previous bad experience of bleeding, espe-
cially in patients with cognitive dysfunction [34] or at
risk of falls [35]; underestimation of the bleeding risk
associated with aspirin [36]; and difficulty in achieving
or maintaining target INR. At the time of stroke, INR
was within therapeutic range in only 36 of the patients
treated with VKA (44.4 %). Several clinical studies
have shown that INR remains within therapeutic range
only 29 % to 75 % of the time [37]. Genetic factors,
chronic comorbidity, diet, concomitant medication
and patient compliance can have an impact on target
INR management [38].
At the start of the present study, CHADS2 scores were
calculated in compliance with the 2006 AF prevention
guidelines. The more recent CHA2DS2 Vasc score re-
vealed a larger proportion of patients requiring anticoa-
gulation, highlighting the importance of updating and
implementing guidelines.
AA prevalence was assessed in all types of stroke
(ischemic, hemorrhagic and “undetermined”) for two rea-
sons. Firstly, patients with “undetermined” stroke a) died
before either arriving at hospital or undergoing brain im-
aging, and b) were either living at home or institutional-
ized with serious comorbidities. “Undetermined” stroke
included severe and fatal stroke. It is known that stroke
associated with AF is more serious than stroke without
AF, due to a higher 30-day case-fatality rate [26]. This led
us to include patients with “undetermined” stroke. Sec-
ondly, hemorrhagic stroke was included in order to esti-
mate the proportion of hemorrhagic strokes associated
with AA among strokes in general, and to determine the
impact of oral anticoagulants on these patients.
The major strength of the present study was its design:
a population-based study including both hospitalized
and non-hospitalized patients. The study evaluated an
older population than in hospital-based studies. Case as-
certainment was quite exhaustive, based on multiple
sources of information. The high level of completeness
and reliability of the Brest Stroke Registry was estab-
lished in our previous study [19]. The present results
represent the step after preliminary validation of the
Registry in 2014.
The limitation of the study was that, given the lack of
adequate duration of AA monitoring in early 2008 (i.e.,
before the opening of specialized stroke units), some
cases of paroxysmal AA may have gone undiagnosed.
Conclusion
The prevalence of AF-related stroke is high in the elderly
and, despite prevention guidelines published 20 years ago,
only a third of the patients at high TE risk are treated with
VKA. We believe that today, with the advent of novel oral
anticoagulants accompanied by the more recent AF guide-
lines [39] based on CHA2DS2 Vasc score, and extensive
patient education programs, physicians are more alert in
the management of patients with AA.
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